Congressionally Directed Medical Research Programs (CDMRP) -- Peer Reviewed Cancer Research Program (PRCRP) -- Translational Science Award

Funding Agency:
Department of Defense

The FY19 PCRP Translational Science Award mechanism supports translational research that will develop promising ideas in prostate cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. As such, applications must include a detailed transition plan that articulates the pathway to moving the project’s findings to the next phase of development after successful completion of the award, and how the Principal Investigator (PI) will continue advancing the research toward making a clinical impact, even if clinical impact is not an immediate outcome. However, PIs should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. The potential impact of the research is expected to be significant and go beyond an incremental advance. Proposed projects may include basic, translational, population science, and/or clinical research, but must demonstrate clinical relevance.

• Required Pre-Application Deadline: June 27, 2019
• Application Submission Deadline: July 18, 2019

Agency Website

Areas of Interest

The mission of the FY19 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. Therefore, applications are required to address one or more of the following FY19 PCRP Overarching Challenges:

• Improve the quality of life for survivors of prostate cancer

• Develop treatments that improve outcomes for men with lethal prostate cancer

• Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

• Define the biology of lethal prostate cancer to reduce death 

Eligibility Requirements

Independent investigators at all levels are eligible to be named as PI on an application for the Translational Science Award.



Amount Description

The anticipated direct costs budgeted for the entire period of performance for an FY19 PCRP TSA will not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Funding Type



Junior Faculty
Medical Fellow/Resident


Medical - Basic Science
Medical - Clinical Science
Medical - Translational
Social Sciences

External Deadline

June 27, 2019